# US 2019/0376128 A1 · Methods and compositions to detect mutations in plasma using exosomal rna and cell free dna from non-small cell lung cancer patients

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0376128 A1
- Document ID: US20190376128A1
- Status: Published application
- Kind: A1
- Application number: 16/463,820
- Filed: 2017-11-17
- Published: 2019-12-12
- Earliest claimed: 2016-11-30
- Assignees: Exosome Diagnostics, Inc.
- Applicants: Exosome Diagnostics, Inc.
- Inventors: Johan Karl Olov SKOG; Elena CASTELLANOS-RIZALDOS; Vasisht TADIGOTLA; Dominik GRIMM; Xuan ZHANG; Wei YU
- Web page: https://patentgrep.com/patent/US20190376128A1

## CPC

- C12Q 1/6851: Quantitative amplification
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/16: Primer sets for multiplex assays
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention relates generally to methods and kits for detecting one or more biomarkers, such as an Epidermal Growth Factor Receptor (EGFR) mutation, e.g., T790M mutation, L858R mutation, one or more exon19 insertions and/or one or more exon19 deletions in the EGFR gene, in a biological sample to aid in diagnosis, prognosis, monitoring, or therapy selection for a disease such as, for example, cancer. The methods and kits are useful in aiding in diagnosis, prognosis, monitoring, or therapy selection for lung cancer, e.g., non-small cell lung cancer (NSCLC).

## Claims

### Claim at position 1

-42. (canceled)

### Claim 43

A method for treating lung cancer in a subject in need thereof comprising:
(a) extracting at least one nucleic acid from at least one microvesicle isolated from a biological sample from the subject;
(b) detecting the amount of at least one Epidermal Growth Factor Receptor (EGFR) variant in the at least one extracted nucleic acid, wherein the at least one EGFR variant comprises EGFRT790M, EGFRL858R, EGFR comprising at least one exon19 insertion, EGFR comprising at least one exon 19 deletion or any combination thereof,
(c) comparing the amount of the at least one EGFR variant to at least one pre-defined cutoff threshold;
(d) administering to the subject at least one anti-cancer therapy when the amount of the at least one EGFR variant is greater than or equal to the at least pre-defined cutoff threshold.

### Claim 44 (depends on 43)

The method of claim 43, wherein detecting in step (b) comprises reverse transcription of the at least one extracted nucleic acid.

### Claim 45 (depends on 44)

The method of claim 44, wherein reverse transcription comprises the use of at least one amplification control, the use of at least one control of inhibition or any combination thereof.

### Claim 46 (depends on 43)

The method of claim 43, further comprising prior to step (a), adding a known quantity of at least one control nucleic acid to the biological sample, and wherein step (b) comprises detecting the amount of the at least one control nucleic acid.

### Claim 47 (depends on 43)

The method of claim 43, further comprising after step (a) and prior to step (b), pre-amplifying the at least one extracted nucleic acid.

### Claim 48 (depends on 47)

The method of claim 47, wherein pre-amplifying the at least one extracted nucleic acids comprises a single-plex pre-amplification of the at least one extracted nucleic acid or a multiplex pre-amplification of the at least one extracted nucleic acid.

### Claim 49 (depends on 47)

The method of claim 47, further comprising after step (a) and prior to step (b), pre-amplifying the at least one extracted nucleic acid under conditions such that the pre-amplification of the at least one EGFR variant is favored.

### Claim 50 (depends on 47)

The method of claim 47, wherein pre-amplifying the at least one extracted nucleic acid comprises the use of at least one wild type blocker for EGFR exon 19, at least one wild type blocker for EGFR exon 20, at least one wild type blocker for EGFR exon 21 or any combination thereof.

### Claim 51 (depends on 50)

The method of claim 50, wherein the wild type blocker comprises a hydrophobic nucleic acid, a bridge nucleic acid, a peptide nucleic acid, an oligonucleotide comprising a 3′ end terminator or any combination thereof.

### Claim 52 (depends on 43)

The method of claim 43, wherein detecting the amount of at least one EGFR variant in the at least one extracted nucleic acid comprises sequencing, next-generation sequencing, PCR, qPCR, PCR-free detection or any combination thereof.

### Claim 53 (depends on 43)

The method of claim 43, wherein detecting the amount of at least one EGFR variant in the at least one extracted nucleic acid comprises qPCR.

### Claim 54 (depends on 53)

The method of claim 53, wherein qPCR comprises a mutant-specific amplification system, a mutation-biased amplification system or any combination thereof.

### Claim 55 (depends on 53)

The method of claim 53, wherein qPCR comprises an Amplification Refractory Mutation system (ARMS).

### Claim 56 (depends on 55)

The method of claim 55, wherein the ARMS comprises at least one primer comprising at least one modified nucleotide, at least one primer comprising at least one modified base, at least one primer comprising at least one modified sequence, at least one probe comprising at least one modified nucleotide, at least one probe comprising at least one modified base, at least one probe comprising at least one modified sequence or any combination thereof.

### Claim 57 (depends on 56)

The method of claim 56, wherein the ARMS comprises at least one primer comprising 2-aminopurine, 8-amino-2′-deoxyadenosine, trimetroxystilbene, C-5 propynyl-deoxycytidine, C-5 propynyl-deoxyuridine, 2-amino-2′-deoxyadenosine-5′-triphosphate, 2,6-diaminopurine (2-amino-dA), inverted dT, inverted dideoxy-T, hydroxymethyl dC, iso-dC, 5-methyl dC, aminoethyl-phenoxazine-deoxycytidine, locked nucleic acids, at least one mismatched base or any combination thereof.

### Claim 58 (depends on 43)

The method of claim 43, wherein the biological sample is a bodily fluid.

### Claim 59 (depends on 43)

The method of claim 43, wherein the lung cancer is non-small cell lung cancer.

### Claim 60 (depends on 43)

The method of claim 43, wherein the anti-cancer therapy comprises administering to the subject at least one therapeutically effective amount of an EGFR inhibitor.

### Claim 61 (depends on 60)

The method of claim 60, wherein the EGFR inhibitor is gefitinib, erlotinib, lapatinib, cetuximab, panitumumab, vandetanib, neratinib, necitumumab, osimertinib or any combination thereof.

### Claim 62 (depends on 43)

The method of claim 43, wherein the anti-cancer therapy comprises administering to the subject at least one therapeutically effective amount of a second generation tyrosine kinase EGFR inhibitor, a third generation tyrosine kinase EGFR inhibitor, an EGFRT790M-targeting compound, an EGFRL858R-targeting compound, a compound that targets EGFR comprising at least one exon 19 insertion, a compound that targets EGFR comprising at least one exon 19 deletion or any combination thereof.

### Claim 63

A method for treating lung cancer in a subject in need thereof comprising:
(a) extracting at least one nucleic acid from at least one microvesicle isolated from a biological sample from the subject;
(b) isolating at least one circulating nucleic acid from the biological sample;
(c) detecting the amount of at least one Epidermal Growth Factor Receptor (EGFR) variant in the at least one extracted nucleic acid and the at least one isolated circulating nucleic acid, wherein the at least one EGFR variant comprises EGFRT790M, EGFRL858R, EGFR comprising one or more exon19 insertions, EGFR comprising one or more exon 19 deletions or any combination thereof,
(d) comparing the amount of the at least one EGFR variant to at least one pre-defined cutoff threshold;
(e) administering to the subject at least one anti-cancer therapy when the amount of the at least one EGFR variant is greater than or equal to the at least pre-defined cutoff threshold.

### Claim 64 (depends on 63)

The method of claim 63, wherein the one or more circulating nucleic acids comprise cell-free DNA, cell-free RNA, necrotic DNA, necrotic RNA or any combination thereof.
